Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2022 Apr 4.
Published in final edited form as: Tetrahedron. 2021 Feb 10;84:131991. doi: 10.1016/j.tet.2021.131991

Preparation of S-2-halophenyl-2,1-benzothiazines

Aswin Garimalla a,b, Michael Harmata a,*
PMCID: PMC8979494  NIHMSID: NIHMS1672361  PMID: 35382242

Abstract

Derivatives of 2,1-benzothiazines are useful synthetic intermediates for a variety of applications. We became interested in developing a one-pot procedure to S-2-halophenyl-2,1-benzothiazines as potential precursors to P,N type ligands for metals. Accordingly, we reacted S-2-halophenyl-S-methylsulfoximines with 2-bromobenzaldehydes using the Buchwald-Hartwig reaction under conditions previously developed in our laboratory. We found that 2-halophenylmethyl sulfoximines show lower reactivity in process than methylphenyl sulfoximine. Among the 2-(S)-2-halophenyl-(S)-methylsulfoximines tested, S-2-fluorophenyl-S-methyl sulfoximine was found to afford higher yields of benzothiazines than the bromine- or chlorine-substituted congeners. In the coupling of S-2-halophenyl-S-methylsulfoximines to 2-bromobenzaldehyde, using Ruphos as a ligand gave the best yields.

Keywords: benzothiazine, sulfoximine, coupling, palladium, organosulfur

Graphical Abstract

To create your abstract, type over the instructions in the template box below.

Fonts or abstract dimensions should not be changed or altered.

graphic file with name nihms-1672361-f0005.jpg

1. Introduction

2,1-Benzothiazines that contain a sulfoximine functional group are a significant class of compounds that find use as chiral ligands,1 building blocks in organic synthesis,2 and fluorophores.3 Other 2,1-benzothiazines have been developed as potential therapeutic agents.4

Our interest in benzothiazine chemistry is long-standing.5 Moreover, a big leap forward in the synthesis of these compounds took place in 1999 when we published a one-pot procedure for the synthesis of these compounds using sulfoximines and 2-halobenzaldehydes and related compounds in conjunction with the Buchwald-Hartwig reaction (Scheme 1)6b using a coupling reaction introduced by Bolm.6a Developments since that time have expanded the scope of this process.7

Scheme 1.

Scheme 1.

A one-pot, one operation approach to 2,1-benzothiazines.

We envisioned that 2-halophenylbenzothiazines would be potential precursors to functionalized new P,N ligands8 and thus would expand the chemistry’s impact further. Our earlier work had demonstrated that the N-arylation of sulfoximines affords benzothiazines very readily (Scheme 1). We wondered if having a halogen substitution ortho to the sulfoximine group on an Smethyl-S-arylsulfoximine would be problematic, especially since one could imagine such sulfoximines coupling to each other to form dimeric, cyclic bis-sulfoximines.

2. Results/Discussion

We began by investigating the reactivity of 2-bromophenyl sulfoximine 4a with 2-bromobenzaldehyde (5) under our standard reaction conditions. While a sulfoximine without a bromine substituent would have reacted to produce the corresponding benzothiazine in high yield, we observed three products, one arising from simple N-arylation (6a, 10%), a condensation product (7a, 52%), and the desired benzothiazine (8a, 9%). Starting material was also recovered (4a, 28%) (Scheme 2). Since our previous work had suggested that condensation products like 7a could not be converted to benzothiazines under the reaction conditions, we deemed that the presence of the bromine atom in 4a slowed coupling, presumably at the ligand exchange stage when the sulfoximine nitrogen becomes bound to the palladium product of oxidative addition to 5. Alternatively, the result could be interpreted as accelerating the condensation reaction leading to 7a. In either case, we wondered if we could optimize the reaction to favor the formation of 8a, and to what extent that might be possible.

Scheme 2.

Scheme 2.

Reaction of S-2-bromophenyl-S-methylsulfoximine (4a) with 2-bromobenzaldehyde.

We first examined the nature of the ligand as well as the Pd source on the course of the reaction. The results are shown in Table 1. At least under conditions of reflux in toluene, the nature of the ligand did not have a strong impact on the outcome of the reaction.

Table 1.

Effects of different Pd sources and ligands on the coupling reactiona

graphic file with name nihms-1672361-t0008.jpg

Entry Pd Ligand 6a (%) 7a (%) 8a (%) 4a (%)

1 Pd2dba3 BINAP 12 55 8 28
2 Pd(PPh3)4 - 8 55 10 30
3 Pd(PPh3)2 Cl2 BINAP 18 58 10 25
4 Pd(OAc)2 P(t-Bu)3 9 48 11 b
5 Pd(OAc)2 Brettphos 10 49 6 b
6 Pd(OAc)2 RuPhos 11 50 7 32
7 Pd(OAc)2 BINAP 10 52 9 28
8 PEPPSI-I - 5 45 6 34
9 PEPPSI-II - 4 43 7 b
a

Yields based on recovered starting material.

b

Starting material not recovered.

b

As the presence of base is also a key factor in the process, the reaction was investigated using different bases (Table 2). Cesium carbonate appeared to perform better than any other bases examined. The use of increasing amounts of base appeared to increase the consumption of 4a but did not have a substantial impact on the yield of 8a (Table 2, entries 3–4). The use of 4Å molecular sieves had no noteworthy effect on the yield of 8a (Table 2, entry 5).

Table 2.

Coupling of 4a and 5 with base variations

graphic file with name nihms-1672361-t0009.jpg

Entry Base (equiv) 6a (%) 7a (%) 8a (%) 4a (%)

1 CsOAc (1.4) 10 52 9 28
2 NaOt-Bu (1.4) 9 45 12 b
3 Cs2CO3 (2.8) 12 55 13 b
4 Cs2CO3 (5.2) 14 55 12 b
S Cs2CO3 (1.4)a 14 46 15 b
a

4 Å MS (20%) were added.

b

Starting material not recovered.

Given earlier success synthesizing benzothiazines from aryl chlorides and sulfoximine under microwave irradiation,9 we decided to investigate the effect of microwaves on the synthetic problem at hand. The reaction time for these reactions was 1.5 h with freshly distilled toluene used as solvent. In most cases, additional catalyst was added to the reaction mixture and the process heating was continued for another 1.5 h. As summarized in Table 3, the results were not impressive, certainly no better than conducting the reaction at reflux.

Table 3.

Coupling of 4a and 5 using microwave irradiation a

graphic file with name nihms-1672361-t0010.jpg

Entry Pd Ligand 6a (%) la (%) 8a (%) 4a (%)

1c,d Pd(OAc)2 BINAP 10 42 11 38
2c,e Pd(OAc)2 BINAP 16 45 10 b
3c,f Pd(OAc)2 BINAP 18 44 15 b
4c Pd2dba3 BINAP 19 48 14 27
5c Pd(PPh3)2 Cl2 - 10 40 12 28
6 Pd(OAc)2 PCy3 14 42 19 29
a

Yields based on recovered starting material.

b

Starting material not recovered.

c

Two reaction cycles performed.

d

One equiv of 5 was used.

e

Three equiv of 5 were used.

f

Five equiv of 5 were used.

We next decided to investigate a different electrophile in the reaction and chose 2-iodobenzaldehyde. Though the Bolm group had shown that iodoarenes are not good candidates for Buchwald-Hartwig couplings using palladium catalysts, we decided to test the compound.10 In the event, the reaction proceeded no better than that 2-bromobenzaldehyde.

Concerned that 4a was undergoing metal-catalyzed processes11 that, though undetected, were deleterious to benzothiazine formation, we decided to investigate the fluorinated sulfoximine 4b. This compound was easily prepared using standard methods for the synthesis of sulfoximine (Scheme 3).12 As we had developed a procedure for the Pd-catalyzed N-arylation of sulfoximines with aryl chlorides in the presence of RuPhos,13 we decided to investigate this ligand in the coupling of 4b with 5 using this ligand. Thus, a slight excess of 4b reacted with 5 in toluene at 120°C in a sealed tube for 3 days to afford 8b in 60% yield, along with 20% of the N-arylation product 6b with complete consumption of 4b (Scheme 4). No special precautions with respect to purging the system with inert gas before beginning the reaction were needed. This result was fortuitously the best result for the coupling of 4b with 5. Other examples with various variable changes are shown in Table 4. Only yields of 8b were recorded. RuPhos and similar ligands perform best in this reaction (Table 4, entries 4, 7–8, 14–16).

Scheme 3.

Scheme 3.

Synthesis of 4b.

Scheme 4.

Scheme 4.

Reaction of 4b with 5.

Table 4.

Optimization studies on the preparation of 8b

graphic file with name nihms-1672361-t0011.jpg

Entry Pd (mol %) Ligand (mol %) Yield (%)

1 Pd(OAc)2 (5) RuPhos (10) 38
2 Pd(PPh3)4 (5) RuPhos (10) 33
3 Pd2(dba)3 (5) BINAP (10) 23
4 Pd2(dba)3 (5) RuPhos (10) 60
S Pd(PPh3)4 (5) - 35
6 Pd2(dba)3 (5) CyDavePhos (10) 35
7 Pd2(dba)3 (5) SPhos (10) 55
8 Pd2(dba)3 (5) BrettPhos (10) 50
9 Pd2(dba)3 (5) t-BuXPhos (10) 20
10 Pd2(dba)3 (5) XantPhos (10) 16
11 Pd2(dba)3 (5) dppf (10) 12
12 Pd2(dba)3 (2.5) RuPhos (10) 42
13 Pd2(dba)3 (5) RuPhos (5) 35
14 Pd2(dba)3 (7.5) RuPhos (10) 53
15 Pd2(dba)3 (5) RuPhos (15) 53
16 Pd2(dba)3 (7.5) RuPhos (15) 57

graphic file with name nihms-1672361-t0007.jpg

With a procedure that yielded useful amounts of benzothiazine 8b in place, the scope of the reaction was expanded to other 2-halophenyl sulfoximines and several 2-bromobenzaldehydes. The results are summarized in Table 5. As expected, under these newly developed conditions, 4a produced only modest yields of the corresponding benzothiazine (Table 5, entries 1, 4, 7,10).

Table 5.

Synthesis of halogenated benzothiazines

graphic file with name nihms-1672361-t0012.jpg

Entry X R1 R2 R3 Product Yield (%)

1 Br H H H 8a 35
2 F H H H 8b 60
3 Cl H H H 8c 45
4 Br −OBn H H 9a 45
5 F −OBn H H 9b 55
6 Cl −OBn H H 9c 50
7 Br H H −OMe 10a 40
8 F H H −OMe 10b 65
9 Cl H H −OMe 10c 60
10 Br H F H 11a 28
11 F H F H 11b 45
12 Cl H F H 11c 42

Unreacted 4a was recovered in all its coupling reaction with different 2-bromobenzaldehydes. The chlorinated sulfoximine 4c gave moderate yields in its coupling reactions (Table 5, entries 3, 6, 9, 12). As expected, yields were best using 4b (Table 5, entries 2, 5, 8, 11). While yields of the benzothiazines reported here are lower than from analogous methods involving non-halogenated sulfoximines, this methodology does allow rapid access to halogenated benzothiazines that to date are not accessible by any other method.

3. Conclusion

In summary, we have developed a route to S-2-halogenophenyl-benzothiazines. The process proceeds in moderate yield, and is much slower than the corresponding reaction using an non-halogenated sulfoximine. Whether the direct introduction of a halogen onto an existing benzothiazine is a better route to such compounds remains to be seen, though some progress has been made in this area.14

4. Experimental section

4.1. General

All reactions were carried out under an argon atmosphere in a flame dried sealed tube except where reported otherwise. CuI was used as purchased from Acros Organics. DMSO was purchased from Drysolv® Acros Organics and distilled over CaH. Acetonitrile was distilled over CaH2. Toluene and THF were distilled over sodium metal and oxygen was removed by generation of a benzophenone ketyl. Pd2dba3, RuPhos, Cs2CO3, LiCl were used as purchased from Aldrich® and used as received. The synthesis of 4ad followed a standard protocol for the synthesis of sulfoximines of this general type.12 All the reaction yields were reported based on the best result, if not stated otherwise.

4.2. Synthesis of Sulfoximines 4: General Procedure.

To a round-bottom flask equipped with a stir bar was added a mixture of sulfide (43.93 mmol) and H2SO4/2-propanol (10 mL, 4.4 M, 4.4 % w/w H2SO4/2-propanol), MeOH (125 mL, 0.4 M). 30% H2O2 (5.5 mL, 53.8 mmol, 1.2 equiv) was added. The reaction mixture was stirred for 4 h at rt. Water (500 mL) was added to the mixture. The aqueous layer was saturated with sodium chloride and extracted with chloroform (3 × 150 mL). The combined organic extracts were dried over magnesium sulfate and evaporated to give the pure sulfoxide for the next reaction. A round-bottom flask equipped with a condenser, a stir bar, a thermometer, and an addition funnel, was charged with a mixture of the sulfoxide, sodium azide (75.2 mmol, 1.71 equiv), and 100 mL of chloroform (0.5 M) and cooled in an ice bath. To this slurry, concentrated sulfuric acid (13.44 mL, 3.2 M) was added over 15 min. The mixture was then carefully warmed up to 45 °C. The mixture was heated further at 45 °C for 12 h. After cooling, 100 mL of ice water was added. After all the salts were dissolved, the chloroform layer was separated, and the aqueous layer was reextracted with 100 mL of chloroform. The aqueous layer was made slightly alkaline with a 20% sodium hydroxide solution and extracted twice with 3 × 100 mL of chloroform. The combined organic extracts were dried over magnesium sulfate, filtered, and the solvent was removed to afford product.

S-(2-Bromophenyl)-S-methyl sulfoximine (4a) and S-(2-chlorophenyl)-S-methyl sulfoximine (4c) were prepared based on the above procedure and displayed 1H NMR and 13C NMR spectra as reported in the literature.5a

4.2.1. S-2-(Fluorophenyl)-S-methyl sulfoximine (4b)

58% yield in two steps following the above procedure from commercially available S-(2-flurophenyl)-S-methyl sulfide. Rf = 0.2 (50% ethyl acetate/hexanes); dull white solid, mp 78–80 °C; IR (CHCl3) 3250, 3140, 2925, 1598, 1472, 1226, 1016, 999, 749 cm−1; 1H NMR (500 MHz, CDCl3) δ 7.98 (dt, J = 7.5, 1.5 Hz, 1H), 7.63–7.58 (m, 1H), 7.32 (dt, J = 7.5, 1.5 Hz, 1H), 7.22 (dt, J = 7.5, 1.Hz, 1H), 3.28 (s, 3H), 3.00 (b, 1H); 13C NMR (125 MHz, CDCl3) δ 160.1(d, J = 2.5 Hz), 135.2 (d, J = 8.75 Hz), 131.4 (d, J = 2.5 Hz), 129.6, 124.5 (d, J = 3.75 Hz), 117.2 (d, J = 21.25 Hz), 44.78 (d, J = 2.5 Hz); HRMS calculated for (C7H8FNOS)Na+: 196.0202, found: 196.0189.

4.3. General procedure for the preparation of S-2-halophenylbenzothiazines. 2-(2-Fluorophenyl) benzo[c][1,2] thiazine-2-oxide (8b) (Procedure A)

2-Bromobenzaldehyde 5 (0.220 g, 1.19 mmol), sulfoximine 4b (0.25 g, 1.43 mmol), Pd2dba3 (0.05459 g, 0.0595 mmol), Cs2CO3 (1.240 g, 3.808 mmol), and Ruphos (0.0554 g, 0.119 mmol) were combined in a sealed tube under open air conditions. Toluene (11.9 mL, 0.1 M) was introduced. The sealed tube was capped and heated to 120 °C in an oil bath for 72 h. After cooling to rt, the reaction mixture was diluted in dichloromethane and filtered through a plug of Celite. The filtrate was concentrated in vacuo, and the resulting brownish semisolid was purified by flash chromatography (SiO2) with 20–30% ethyl acetate/hexanes to afford 0.184 g of 8b (60% yield) as pale brown solid; Rf = 0.4 (30% ethyl acetate/hexanes); 60% yield; mp 117–119 °C; IR (CHCl3) 3059, 2928, 2918, 1607, 1520, 1450, 1286, 1047, 998, 884, 784, 727, 684 cm−1; 1 H NMR (500 MHz, CDCl3) δ 8.04 (dt, J = 8, 1.5 Hz, 1H), δ 7.70 (d, J = 10 Hz, 1H), δ 7.62–7.60 (m, 1H), 7.46 (t, J = 7 Hz, 1H), 7.33–7.35 (m, 2H), 7.29 (d, J = 7.5 Hz, 1H), 7.20 (t, J = 9.5, 9 Hz, 1H), 7.02 (t, J = 9.5, 9 Hz, 1H), 6.39 (d, J = 9.5 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 160.5, 158.5, 145.1, 140.6, 136.0, 135.9, 132.3, 129.8, 129.7, 129.6, 129.4, 124.37, 124.34, 123.9, 120.3, 117.6, 117.4, 116.1, 108.9, 108.8; HRMS calculated for (C14H10FNOS)Na+: 282.0359; found: 282.0361.

4.3.1. 2-(((2-Fluorophenyl)(methyl)(oxo)-λ6-sulfaneylidene)amino) benzaldehyde (6b)

Purified by column chromatography (SiO2) using 30% ethyl acetate/hexanes, Rf = 0.35 (30% ethyl acetate/hexanes); pale yellow crystals from 50% ethyl acetate/hexanes; 20% yield; mp 83–85 oC; IR (CHCl3) 3030, 2960, 2849, 1683, 1660, 1595, 1473, 1384, 1216, 1286, 1075, 1024, 998, 884, 784, 727, 684 cm−1; 1H NMR (500 MHz, CDCl3) δ 10.6 (s, 1H), 8.02 (dt, J = 8.5, 1.5 Hz, 1H), δ 7.76 (dd, J = 7.5, 1.5 Hz, 1H), 7.60 (m, 1H), 7.33 (t, J = 7.5 Hz, 1H), 7.27–7.20 (m, 2H ), 7.17 (t, J = 9.5 Hz, 1H), 7.11 (d, J = 8 Hz, 1H), 6.94 (t, J = 7.5 Hz, 1H), 3.48 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 192.4, 159.8 (d, J = 253.75 Hz) 148.2, 136.1 (d, J = 8.75 Hz), 134.7, 131.7, 129.6, 127.7, 126.4 (d, J = 13.75 Hz), 124.9 (d, J = 3.75 Hz), 122.9, 122.7, 117.5 (d, J = 21.25 Hz), 45.29 (d, J = 2.5 Hz); HRMS calculated for (C14H12FNO2S)Na+: 300.0464; found: 300.0467.

4.3.1.1. Crystal Structure of compound 6b

C14H12FNO2S, M = 277.31; a block crystal (0.50 × 0.45 × 0.35 mm), T = 173(2) K, λ = 0.71073 Å, orthorhombic, space group: P21/n, a = 14.2559(12) Å, b = 11.0583(9) Å, c = 16.5580(14) Å, V = 2610.3(4) Â3, 22369 total reflections, 17735 unique, Rint = 0.0279 R1 = 0.0345 (I > 2s), wR2 = 0.0865, Flack parameter: 0.44(6).

4.3.2. 2-(2-Chlorophenyl)benzo[c][1,2]thiazine-2-oxide (8c)

Purified by column chromatography (SiO2) using 30% ethyl acetate/hexanes; pale yellow solid, Rf = 0.4 (30% ethyl acetate/hexanes), 45% yield; mp 178–180 °C; IR (CHCl3) 3059, 2928, 2918, 1607, 1520, 1450, 1215, 1170, 1047, 998, 884, 784, 727, 684 629cm−1; 1H NMR (500 MHz, CDCl3) δ 8.35 (dd, J = 7, 2 Hz, 1H), δ 7.78 (d, J = 9.5 Hz, 1H), δ 7.57–7.55 (m, 4H), 7.53 (t, J = 7.0 Hz, 1H), 7.48 (d, J = 8 Hz, 1H ), 7.29 (t, J = 7.0 Hz, 1H), 7.07 (t, J = 7 Hz, 1H), 6.39 (d, J = 9.5 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 145.5, 141.6, 138.0, 135.7, 134.5, 132.4, 132.3, 130.4, 129.8, 127.0, 124.0, 120.2, 116.3, 107.3; HRMS calculated for (C14H10ClNOS)Na+: 298.0063, found: 298.0068.

4.3.3. 6-(Benzyloxy)-2-(2-bromophenyl) benzo[c] [1,2] thiazine 2-oxide (9a)

Purified by column chromatography (SiO2) using 30% ethyl acetate/hexanes, greenish yellow liquid; 45% yield; IR (CHCl3) 3067, 2925, 2824, 1733, 1652, 1539, 1496, 1286, 1215, 1041, 990, 829, 749, 668 cm-1; 1H NMR (500 MHz, CDCl3) δ 8.24 (dd, J = 8.5, 1.5 Hz, 1H), 7.74 (dd, J = 8.0, 1.0 Hz, 1H), 7.70 (d, J = 10 Hz, 1H), 7.55 (dt, J = 7.5, 1 Hz, 1H), 7.45–7.42 (m, 3H), 7.38–7.35 (m, 2H), 7.35–7.33 (m, 1H), 7.20 (d, J = 1.5 Hz, 2H), 6.99 (d, J = 1.5 Hz, 1H), 6.33 (d, J = 10 Hz, 1H). 5.07 (s, 2H); 13C NMR (125 MHz, CDCl3) δ 152.4, 141.1, 140.1, 139.0, 136.9, 135.8, 134.4, 130.9, 128.6, 128.0, 127.5, 125.2, 124.8, 122.3, 116.2, 107.1, 70.7; HRMS calculated for (C21H16BrNO2S)Na+: 447.9977, found: 447.9977.

4.3.4. 6-(benzyloxy)-2-(2-fluorophenyl) benzo [c] [1,2] thiazine 2-oxide (9b)

Purified by column chromatography (SiO2) using 30% ethyl acetate/hexanes; yellow sticky liquid; 55% yield; IR (CHCl3) 3067, 2929, 2863, 1673, 1590, 1472, 1226, 1016, 990, 829, 749, 668 cm-1; 1H NMR (500 MHz, CDCl3) δ 8.04 (dt, J= 7.5, 1.5 Hz, 1H), 7.64 (d, J = 10 Hz, 1H), 7.64–7.62 (m, 2H), 7.44–7.43 (m, 2H), 7.34–7.33 (m, 2H), 7.25–7.23 (m, 1H), 7.19–7.18 (m, 2H), 6.89 (d, J = 3 Hz, 1H), 6.52 (d, J = 10 Hz, 1H). 5.07(s, 2H); 13C NMR (125 MHz, CDCl3) δ 160.5 (d, J = 256.25 Hz), 152.4, 139.9 (d, J = 25 Hz), 136.9, 135.9 (d, J = 7.5 Hz), 129.5 (d, J = 11.25 Hz), 128.6, 128.0, 127.5 (d, J = 12.5 Hz), 125.0, 124.3 (d, J = 5 Hz), 122.1, 117.5 (d, J = 21.25 Hz), 116.1, 112.6, 109.0, 70.71; HRMS calculated for (C21H16FNO2S)Na+: 388.0777; found: 388.0775.

4.3.5. 6-(Benzyloxy)-2-(2-chlorophenyl) benzo [c] [1,2] thiazine 2-oxide (9c)

Purified by column chromatography (SiO2) using 30% ethyl acetate/hexanes; pale yellow oil; 50% yield; IR (CHCl3) 3067, 2925,, 1652, 1590, 1472, 1215, 1170, 1023, 990, 829, 749, 668 593 cm-1; 1H NMR (500 MHz, CDCl3) δ 8.33 (d, J= 8 Hz, 1H), 7.69 (d, J = 10 Hz, 1H), 7.53–7.50 (m, 3H), 7.44–7.38 (m, 2H), 7.40 (t, J = 7.5 Hz, 2H), 7.20–7.19 (m, 1H), 6.90 (d, J = 2 Hz, 1H), 6.37 (d, J = 10 Hz, 1H). 5.07 (s, 2H) 13C NMR (125 MHz, CDCl3) δ 152.4, 140.9, 140.0, 138.0, 137.0, 135.7, 134.5, 132.2, 130.5, 128.6, 128.0, 127.5, 125.0, 125.1, 122.2, 116.0, 112.6, 107.5, 70.7; HRMS calculated for (C21H16ClNO2S)Na+: 404.0482, found: 404.0490.

4.3.6. 2-(2-Bromophenyl)-8-methoxybenzo [c] [1,2] thiazine 2-oxide (10a)

Purified by column chromatography (SiO2) using 30% ethyl acetate/hexanes; pale yellow solid; 40% yield; mp 173–175 °C; IR (CHCl3) 3057, 2992, 2937, 2836, 1601, 1599, 1429, 1372, 1175, 1080, 997, 807, 720, 668 cm−1; 1H NMR (500 MHz, CDCl3) δ 8.44 (dt, J = 7.5, 1.5 Hz, 1H), 7.77 (d, J = 10 Hz, 1H), 7.70 (d, J = 8 Hz, 1H), 7.53 (t, J = 7.5, 8.5 Hz, 1H), 7.42 (dt, J = 7.5, 6 Hz, 1H), 7.02–6.97 (m, 3H), 6.31 (d, J = 10 Hz, 1H). 3.92(s, 3H); 13C NMR (125 MHz, CDCl3) δ 151.9, 141.6, 138.9, 135.8, 135.6, 134.3, 131.0, 127.3, 125.2, 121.7, 119.6, 116.7, 112.5, 107.0, 56.1; HRMS calculated for (C15H12BrNO2S) Na+: 371.9664, found: 371.9662.

4.3.7. 2-(2-Fluorophenyl)-8-methoxybenzo [c] [1,2] thiazine 2-oxide (10b)

Purified by column chromatography (SiO2) using 30% ethyl acetate/hexanes; pale yellow solid recrystallized from ethyl acetate/hexane, 65% yield; mp 168–170 oC; IR (CHCl3) 3064, 2986, 2937, 2837, 1599, 1547, 1472, 1289, 1257, 1000, 997, 828, 720, 682, 593 cm−1; 1H NMR (500 MHz, CDCl3) δ 8.09 (dt, J = 7.5, 1.5 Hz, 1H), 7.72 (d, J = 10 Hz, 1H), 7.60–7.59 (m, 2H), 7.35 (t, J = 7.5, 8.5 Hz, 1H), 7.16 (dt, J = 9.5, 8.5 Hz, 1H), 7.01–6.97 (m, 3H), 6.50 (d, J = 10 Hz, 1H). 3.94 (s, 3H) 13C NMR (125 MHz, CDCl3) δ 161.0, (d, J = 256.25 Hz), 151.9, 140.5, 136.1 (d, J = 8.75 Hz), 135.5, 135.9 (d, J = 7.5 Hz), 129.9, 129.5 (d, J = 11.25 Hz), 124.17 (d, J = 3.75 Hz), 121.7, 119.7, 117.5 ( d, J = 20 Hz), 116.6, 112.6, 109.0, 56.1; HRMS calculated for (C15H12FNO2S)Na+: 312.0464, found: 312.0463.

4.3.7.1. Crystal Structure of compound 10b

C14H12FNO2S, M = 289.32; a block crystal (0.55 × 0.14 × 0.10mm), T = 173(2) K, λ = 0.71073 Å, trigonal, space group: P21/n, a = 30.100(13) Å, b = 30.100(13) Å, c = 7.609(3)Å, V = 5970(4) Â3, 22369 total reflections, 3049 unique, R int = 0.0279 R1 = 0.0255(I > 2s), wR2 = 0.0628, Flack parameter: 0.00 (5).

4.3.8. 2-(2-Chlorophenyl)-8-methoxybenzo [c] [1,2] thiazine 2-oxide (10c)

Purified by column chromatography (SiO2) using 30% ethyl acetate/hexanes; pale yellow solid recrystallized from ethyl acetate/hexane; 60% yield; mp 185–187 °C; IR (CHCl3) 3057, 2992, 2937, 2836, 1601, 1599, 1429, 1372, 1215, 1170, 1080, 997, 807, 720, 668 cm−1; 1H NMR (500 MHz, CDCl3) δ 8.44 (dt, J = 7.5, 1.5 Hz, 1H), 7.77 (d, J = 10 Hz, 1H), 7.70 (d, J = 8 Hz, 1H), 7.53 (t, J = 7.5, 8.5 Hz, 1H), 7.42 (dt, J = 7.5, 6 Hz, 1H), 7.02–6.97 (m, 3H), 6.31 (d, J = 10 Hz, 1H). 3.92 (s, 3H) 13C NMR (125 MHz, CDCl3) δ 151.9, 141.6, 138.9, 135.8, 135.6, 134.3, 131.0, 127.3, 125.2, 121.7, 119.6, 116.7, 112.5, 107.0, 56.1; HRMS calculated for (C15H12ClNO2S)Na+: 328.0169, found: 328.0172.

4.3.9. 2-(2-Bromophenyl)-7-fluorobenzo [c] [1,2] thiazine 2-oxide (11a)

Purified by column chromatography (SiO2) using 30% ethyl acetate/hexanes, yellow sticky liquid, Rf = 0.4 (30% ethyl acetate/hexanes), 28% yield; IR (CHCl3) 3072, 3035, 2928, 1605, 1539, 1496, 1286, 1215, 1041, 907, 884, 784, 727, 676, 569, cm-1; 1H NMR (500 MHz, CDCl3) δ 8.41 (dd, J = 7.0, 1.0 Hz, 1H), δ 7.76 (d, J = 8 Hz, 1H), δ 7.74 (d, J = 10 Hz, 1H), 7.59 (t, J = 7.5 Hz, 1H), 7.48 (t, J = 7.5 Hz, 1H ), 7.34 (dd, J = 6.5, 2.5 Hz, 1H), 6.93 (dt, J = 10.5, 2 Hz, 1H), 6.76 (dt, J = 8.0, 2.0 Hz, 1H ), 6.28 (d, J = 10 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ166.3 (d, J = 250 Hz), 147.6 (d, J = 13.75 Hz), 141.2, 138.7, 135.9, 134.6, 131.8 (d, J = 11.25 Hz), 130.8, 129.1, 128.7, 127.7, 124.7, 113.2, 109.7 (d, J = 22.5 Hz), 109.1 (d, J = 23.75 Hz), 105.8 (d, J = 2.5 Hz); HRMS calculated for (C14H9BrFNOS)Na+: 359.9564, found: 359.9474.

4.3.10. 7-Fluoro-2-(2-fluorophenyl) benzo [c] [1,2] thiazine 2-oxide (11b)

Purified by column chromatography (SiO2) using 30% ethyl acetate/hexanes, sticky liquid, Rf = 0.4 (30% ethyl acetate/hexanes); 45% yield; IR (CHCl3) 3040, 2918, 1607, 1520, 1450, 1286, 1047, 998, 890, 784, 727, 626 cm−1; 1H NMR (500 MHz, CDCl3) δ 8.04 (dt, J = 8, 1.5 Hz, 1H), 7.68 (d, J = 10 Hz, 1H), 7.64–7.63 (m, 1H), 7.36 (t, J = 8 Hz, 1H), 7.35 (m, 1H ), 7.19 (t, J = 9 Hz, 1H), 6.93 (dd, J = 11, 2.5 Hz, 1H), 6.77 (dt, J = 8, 2.5 Hz, 1H), 6.46 (d, J = 10 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 166.3(d, J = 250 Hz), 160.6 (d, J = 255 Hz), 147.2 (d, J = 13.75 Hz), 140.1, 136.2 (d, J = 8.75 Hz), 131.7 (d, J = 11.25 Hz), 129.4 (d, J = 12.5 Hz), 124.4 (d, J = 3.75 Hz), 117.6 (d, J = 21.25 Hz), 113.01 (d, J = 1.25 Hz), 109.6 (d, J = 22.5 Hz), 109.1 (d, J = 23.75 Hz), 107.6; HRMS calculated for (C14H9F2NOS)Na+: 300.0265, found: 300.0270.

4.3.11. 2-(2-Chlorophenyl)-7-fluorobenzo [c] [1,2] thiazine 2-oxide (11c)

Purified by column chromatography (SiO2) using 30% ethyl acetate/hexanes; sticky liquid; Rf = 0.4 (30% ethyl acetate/hexanes); 42% yield; IR (CHCl3) 3040, 2908, 1616, 1512, 1450, 1215, 1170 1046, 978, 854, 727, 684 646 cm−1; 1H NMR (500 MHz, CDCl3) δ 8.32 (d, J = 6.0, 1.5 Hz, 1H), 7.72 (d, J = 10 Hz, 1H), 7.54–7.53 (m, 3H), 7.35 (dd, J = 6.5, 2. Hz, 1H), 6.93 (dd, J = 11, 2.5 Hz, 1H ), 6.76 (dt, J = 2.5, 0.5 Hz, 1H), 6.39 (d, J = 10 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 166.3 (d, J = 250 Hz), 147.5 (d, J = 13.75 Hz), 141.0, 137.7, 135.7, 134.7, 132.3, 131.8 (d, J = 11.25 Hz), 130.4, 127.1, 113.0, 109.6 (d, J = 22.5 Hz), 109.0 (d, J = 23.75 Hz), 106.2 (d, J = 2.5 Hz); HRMS calculated for (C14H9ClFNOS)Na+: 315.9969, found: 315.9976.

4.4. Typical Procedure for the coupling reaction of 2-bromophenyl sulfoximine 4a with 5 (Procedure B).

2-Bromobenzaldehyde 5 (0.164 g, 0.89 mmol), sulfoximine 4a (0.25 g, 1.06 mmol), Pd(OAc)2 (0.0100 g, 0.0443 mmol), Cs2CO3(0.405 g, 1.24 mmol), BINAP (0.0415 g, 0.0667 mmol) were added together in a sealed tube with toluene (8.9 mL, 0.1 M) inside a glove bag filled with nitrogen and capped. The mixture was degassed by bubbling with argon for 15 min with stirring at rt and heated to 110 °C for 48 h. After cooling to rt, the reaction mixture was diluted in dichloromethane and filtered through a plug of celite. After concentrated in vacuo, the brownish semisolid was purified by flash chromatography (SiO2) with 20–30% ethyl acetate/hexanes to afford 0.159 g of 7a (52%) as pale yellow solid, 0.023 g of 6a (10%), 0.028 g of 8a (9%) and 0.07 g of 4a (28%) were recovered.

4.4.1. 2-(((2-Bromophenyl) (methyl) (oxo)-λ6-sulfaneylidene) amino)benzaldehyde (6a)

Purified by column chromatography (SiO2) using 30% ethyl acetate/hexanes, pale yellow solid, mp 129–131 °C; Rf = 0.35 (30% ethyl acetate/hexanes); 12% yield; IR (CHCl3) 3024,2963, 2927, 2849, 1681, 1657, 1593, 1571, 1474, 1451, 1320, 1216, 1102, 1075, 1013, 960, 831, 784, 727, 684 530 cm−1; 1H NMR (500 MHz, CDCl3) δ 10.7 (s, 1H), 8.36 (dd, J = 8.0, 1.5 Hz, 1H), δ 7.79 (dd, J = 8, 1.5 Hz, 1H), δ 7.69 (dd, J = 8.0, 0.5 Hz, 1H), 7.55 (t, J = 7.5 Hz, 1H), 7.44 (t, J = 7.5 Hz, 1H), 7.19 (dt, J= 6.5, 0.5 Hz, 1H), 6.97 (d, J = 8.5 Hz, 1H), 6.94 (t, J = 7.5 Hz, 1H), 3.55 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 192.6, 148.1, 137.7, 135.9, 134.7, 134.7, 133.4, 129.2, 128.2, 127.8, 122.0, 121.8, 120.3, 43.8; HRMS calculated for (C14H12BrNO2S)Na+: 359.9664, found: 359.9673.

4.4.2. (E)-(2-Bromophenyl) (2-bromostyryl) (imino)-λ6-sulfanone (7a)

Purified by column chromatography (SiO2) using 50% ethyl acetate/hexanes, pale yellow solid crystallized in 50% ethyl acetate/hexanes, Rf = 0.35 (50% ethyl acetate/hexanes); 55% yield; mp 124–127 °C; IR (CHCl3) 3329, 3264, 3062, 2929, 1609, 1439, 1239, 1215, 1112, 1027, 969, 851, 814, 752, 667, 699, 644, 554 cm−1; 1H NMR (500 MHz, CDCl3) δ 8.36 (d, J = 8.Hz, 1H), 8.15 (d, J = 15 Hz, 1H), 7.74 (d, J = 8.0 Hz, 1H), 7.63 (d, J = 8.0 Hz, 1H), 7.58 (d, J = 7.5 Hz, 1H), 7.52 (t, J = 7.5 Hz, 1H), 7.39 (t, J= 7.5 Hz, 1H), 7.33 (t, J = 7.5 Hz, 1H), 7.27–7.26 (m, 1H), 7.18 (d, J= 15 Hz, 1H), 3.17 (s, br, 1H); 13C NMR (125 MHz, CDCl3) δ 142.8, 142.0, 135.6, 133.9, 133.6, 132.8, 131.9, 130.9, 129.4, 128.4, 128.0, 127.8, 125.6, 120; HRMS calculated for (C14H11Br2NOS)Na+: 421.8820, found: 421.8820.

4.4.2.1. Crystal Structure of compound 7a

C14H11Br2NOS, M = 400.11; a block crystal (0.50 × 0.50 × 0.20 mm), T = 173(2) K, λ = 0.71073 Å, monoclinic, space group: P21/n, a = 14.7558(16) Å, b = 14.6322(16) Å, c = 14.9319(17) Å, V = 2896.3(6) Â3, 20085 total reflections, 6367 unique, Rint = 0.0563 R1 = 0.0655 (I > 2s), wR2 = 0.1709.

4.4.3. 2-(2-Chlorophenyl)-7-fluorobenzo [c][ 1,2] thiazine 2-oxide (8a).

Purified by column chromatography (SiO2) using 30% ethyl acetate/hexanes, pale yellow solid recrystallized from 50% ethyl acetate/hexanes, mp 189–191 °C; Rf = 0.4 (30% ethyl acetate/hexanes); 35% yield; IR (CHCl3) 3052, 3013, 2928, 1605, 1527, 1450, 1178, 1047, 995, 884, 784, 727, 676, 569, cm−1; 1H NMR (500 MHz, CDCl3) δ 8.43 (dd, J= 7.5, 1.0 Hz, 1H), 7.78 (d, J = 10.0 Hz, 1H), 7.75 (d, J = 8.0 Hz, 1H), 7.56 (t, J = 7.5, Hz, 1H), 7.46 (dd, J = 7.5 1Hz, 2H ), 7.38 (d, J = 7 Hz, 1H), 7.27 (t, J = 7.5 Hz, 1H), 7.03 (t, J = 7.5 Hz, 1H ), 6.34 (d, J = 10.0 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 145.5, 141.8, 139.1, 135.8, 134.5, 132.4, 130.8, 129.8, 127.6, 124.7, 124.1, 120.2, 116.3, 107.0; HRMS calculated for (C14H10BrNOS)Na+: 341.9558, found: 341.9566.

4.4.3.1. Crystal Structure of compound 8a

C14H10BrNOS, M = 320.20; a block crystal (0.50 × 0.15 × 0.15 mm), T = 173(2) K, λ = 0.71073 Å, Orthorhombic, space group: P 21 21 21, a = 6.1056(3) Å, b = 9.9557(5) Å, c = 20.7650(11) Å, V = 1262.21(11) Â3, 9063 total reflections, 2771 unique, Rint = 0.0305 R1 = 0.0266 (I > 2s), wR2 = 0.0539, Flack parameter: 0.492(8).

4.5. General Procedure for the coupling reaction of S-(2-bromophenyl)-S-methyl sulfoximine 4a with 5 under microwave irradiation. (Procedure C)

In a microwave tube kept inside a glove bag filled with nitrogen, 2-bromobenzaldehyde 5 (0.164 g, 0.89 mmol), sulfoximine 4a (0.25 g, 1.06 mmol), Pd(OAc)2 (10 mg, 0.0443 mmol), Cs2CO3 (0.405 g, 1.24 mmol), BINAP (0.0415 g, 0.0667 mmol) were added. Toluene (8.9 mL, 0.1 M) was introduced and the tube was capped. The microwave tube was taken out of the glove bag and the reaction mixture was degassed by bubbling with argon for 15 min with stirring at rt. The reaction was heated to 110 °C in a microwave reactor for 1.5 h. After cooling to room temperature, Pd(OAc)2 (0.0100 g, 0.0443 mmol), Cs2CO3 (0.405 g, 1.24 mmol), BINAP (0.0415 g, 0.0667 mmol) were added again and the reaction was heated to 110 °C for another 1.5 h. After cooling to room temperature, the reaction mixture was diluted in dichloromethane and filtered through a plug of Celite. The filtrate was concentrated in vacuo, the resulting brown semisolid was purified by flash chromatography (SiO2) with 20–30% ethyl acetate/hexanes to afford 0.149 g of 7a (42%), 0.029g of 6a (10%), 0.030 g of 8a (11%) and 0.095 g of 4a (38% recovered).

Supplementary Material

1
2
3
4
5
  • Synthesis of functionalized 2,1-benzothiazines

  • Benzothiazine Ssynthesis via Buchwald-Hartwig reaction

  • One-pot, three bond formation of benzothiazines

Acknowledgments

Financial support for this work was provided by the by the NIH (1RO1-AI59000-01 A1). Thanks to Prof. Michael Organ for a gift of PEPPSI- and PEPPSI-II. Thanks to Dr. Charles L. Barnes (Missouri) for acquisition of X-ray data. Thanks to Alexander S. Harmata for proofreading a revised version of the manuscript.

Footnotes

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Declaration of interests

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Supplementary Material

1H and 13C NMR spectra for all new compounds (PDF)

Crystallographic Information for 7a (CIF)

Crystallographic Information for 8a (CIF)

Crystallographic Information for 6b (CIF)

Crystallographic Information for 10b (CIF)

References and notes

  • 1.Harmata M; Ghosh SK Org. Lett 2001, 3, 3321–3323. [DOI] [PubMed] [Google Scholar]
  • 2.(a) Selected examples: Chen Y; Harmata M. Tetrahedron Lett. 2011, 52, 4069–4071. [DOI] [PMC free article] [PubMed] [Google Scholar]; (b) Harmata M; Cai Z; Chen YJ Org. Chem 2009, 74, 5559–5561. [DOI] [PMC free article] [PubMed] [Google Scholar]; (c) Harmata M; Ying W; Hong X; Barnes CL Synthesis. 2008, 594–604. [Google Scholar]
  • 3.Yongpruksa N; Pandey S; Baker GA; Harmata M. Org. Biomol. Chem 2011, 9, 7979–7982. [DOI] [PubMed] [Google Scholar]
  • 4.(a) Selected recent examples: Ahmad S; Jalil S; Zaib S; Aslam S; Ahmad M; Rasul A; Arshad MN; Sultan S; Hameed A; Asiri AM; Iqbal J. Eur. J. Pharm. Sci 2019, 131, 9–22. [DOI] [PubMed] [Google Scholar]; (b) Cannalire R; Tarantino D; Astolfi Barreca M. L.; Saba-tini S; Massari S; Tabarrini O; Milani M; Querat G; Mastran-gelo E; Manfroni G; Cecchetti V. Eur. J. Med. Chem 2018, 143, 1667–1676. [DOI] [PubMed] [Google Scholar]; (c) Ukrainets IV; Petrushova LA; Dzyubenko SP; Grinevich LA; Sim G. Pharm. Chem. J 2017, 51, 553–557. [Google Scholar]; (d) Ukrainets IV; Petrushova LA; Dzyubenko SP; Liu Y. Chem. Heterocycl. Compd 2014, 50, 564–572. [Google Scholar]; (e) Tomita N; Hayashi Y; Suzuki S; Oomori Y; Aramaki Y; Matsushita Y; Iwatani M; Iwata H; Okabe A; Awazu Y; Isono O; Skene RJ; Hosfield DJ; Miki H; Kawamoto T; Hori A; Baba A. Bioorg. Med. Chem. Lett 2013, 23, 1779–1785. [DOI] [PubMed] [Google Scholar]
  • 5.(a) Selected examples: Garimallaprabhakaran A; Hong X; Harmata M. ARKIVOC 2012, 119–128. [Google Scholar]; (b) Harmata M; Rayanil K.-o.; Espejo VR; Barnes CL J. Org. Chem 2009, 74, 3214–3216. [DOI] [PMC free article] [PubMed] [Google Scholar]; (c) Harmata M; Hong XJ Am. Chem. Soc 2003, 125, 5754–5756. [DOI] [PubMed] [Google Scholar]
  • 6.(a) Bolm C; Hildebrand JP Tetrahedron Lett. 1998, 39, 5731–5734. [Google Scholar]; (b) Harmata M; Pavri N. Angew. Chem., Int. Ed 1999, 38, 2419–2422. [DOI] [PubMed] [Google Scholar]
  • 7.(a) Chattopadhyay SK Synth. Commun 2018, 48, 3033–3078. [Google Scholar]; (b) Battula SRK; Subbareddy GV; Chakravarthy IE; Saravanan V. RSC Adv. 2016, 6, 55710–55714. [Google Scholar]
  • 8.(a) Carroll MP; Guiry P. J. Chem. Soc. Rev 2014, 43, 819–833. [DOI] [PubMed] [Google Scholar]
  • 9.Harmata M; Hong X. Synlett 2007, 969–973. [Google Scholar]
  • 10.Bolm C; Hildebrand JP J. Org. Chem 2000, 65, 169–175. [DOI] [PubMed] [Google Scholar]
  • 11.Harmata M; Rayanil K.-o.; Gomes MG; Zheng P; Calkins NL; Kim S-Y; Fan Y; Bumbu V; Lee DR; Wacharasindhu S; Hong X. Org. Lett 2005, 7, 143–145. [DOI] [PubMed] [Google Scholar]
  • 12.Reggelin M; Zur C. Synthesis 2000, 1–64. [Google Scholar]
  • 13.Yongpruksa N; Calkins NL; Harmata M. Chem. Commun 2011, 47, 7665–7667. [DOI] [PubMed] [Google Scholar]
  • 14.(a) Calkins NL; Harmata M. Synthesis 2013, 45, 1785–1790. [Google Scholar]; (b) Calkins NL; Hampton CS; Harmata M. Heterocycles 2016, 93, 411–421. [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

1
2
3
4
5

RESOURCES